<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684212</url>
  </required_header>
  <id_info>
    <org_study_id>G-200316</org_study_id>
    <nct_id>NCT04684212</nct_id>
  </id_info>
  <brief_title>Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF Valvular AF</brief_title>
  <acronym>CORRAL-AF</acronym>
  <official_title>Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (CORRAL-AF) IDE Registry Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brian O'Neill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the safety and efficacy of the implantation of the&#xD;
      LAmbreTM device in patients with large or irregularly shaped appendages with non-valvular&#xD;
      atrial fibrillation who are at increased risk for stroke and systemic embolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single center, pilot study will enroll a total of 15 patients. Patients&#xD;
      presenting with non-valvular atrial fibrillation who are at increased risk for stroke and&#xD;
      systemic embolism based on CHA2DS2-VASc scores, and who are recommended for oral&#xD;
      anticoagulation therapy but have an appropriate rationale to seek a non-pharmacologic&#xD;
      alternative to oral anticoagulation, and who meet all eligibility criteria will be enrolled&#xD;
      in the study.&#xD;
&#xD;
      Subjects will have clinical follow-up in-hospital and at 45 days, 6 months, 12 months, and 2,&#xD;
      3, 4, and 5 years. Transesophageal echocardiographic (TEE) or CT follow-up will occur at 45&#xD;
      days.&#xD;
&#xD;
      The LAmbreTM Left Atrial Appendage (LAA) Closure System is intended to reduce the risk of&#xD;
      thromboembolism from the left atrial appendage (LAA) in patients with nonvalvular atrial&#xD;
      fibrillation who:&#xD;
&#xD;
        -  Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc&#xD;
           scores and are recommended for oral anticoagulation (OAC) therapy; AND&#xD;
&#xD;
        -  Are deemed by their physician to be suitable for OAC; AND&#xD;
&#xD;
        -  Have an appropriate rationale to seek a non-pharmacological alternative to OAC, taking&#xD;
           into account the safety and effectiveness of the device compared to OAC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This prospective, single center, pilot study will enroll a total of 15 patients.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall safety, assessed at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Major procedure-related complications, defined as the composite of cardiac perforation, pericardial effusion with tamponade, device embolization, and major vascular complications AND major adverse events, defined as all death, all stroke and major bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Overall efficacy, defined as the composite of cardiovascular death, ischemic stroke, and systemic embolization, evaluated throughout the time on study and Efficacy will be assessed when all subjects have reached at least the 12-month follow-up time point (assuming a 24-month enrollment period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appendage Closure Success</measure>
    <time_frame>45 days</time_frame>
    <description>Closure success, defined as technical success followed by successful LAA closure (complete LAA closure or peri-device residual jet &lt;4 mm in width by TEE or CT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Left Atrial Appendage Thrombosis</condition>
  <condition>CVA</condition>
  <arm_group>
    <arm_group_label>LAmbreTM Left Atrial Appendage Closure System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single center, pilot study will enroll a total of 15 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAmbreTM Left Atrial Appendage Closure System</intervention_name>
    <description>The LAmbre device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.</description>
    <arm_group_label>LAmbreTM Left Atrial Appendage Closure System</arm_group_label>
    <other_name>LAmbre device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is a male or non-pregnant female ≥18 years of age&#xD;
&#xD;
          2. The patient has documented paroxysmal, persistent, or permanent non- valvular atrial&#xD;
             fibrillation&#xD;
&#xD;
          3. The patient has a CHADS2 score ≥ 2 or a CHA2DS2-VASc score of ≥ 3, and is recommended&#xD;
             for oral anticoagulation therapy&#xD;
&#xD;
          4. The patient is deemed by their physician to be suitable for short-term warfarin&#xD;
             therapy, but there is an appropriate rationale for seeking a non-pharmacologic&#xD;
             alternative to oral anticoagulation&#xD;
&#xD;
          5. The patient is deemed suitable for LAA closure in a shared decision model with a&#xD;
             non-implanting physician&#xD;
&#xD;
          6. The patient is willing and able to comply with protocol-specified treatment and&#xD;
             follow-up evaluations&#xD;
&#xD;
          7. The patient (or his or her legally authorized representative) has been informed of the&#xD;
             nature of the study, agrees to its provisions, and has been provided written informed&#xD;
             consent approved by the appropriate Institutional Review Board (IRB) or Ethics&#xD;
             Committee (EC)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female patients of childbearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to index procedure per site standard&#xD;
             test.&#xD;
&#xD;
          2. Patients with atrial fibrillation that is defined by a single occurrence, or that is&#xD;
             transient or reversible (e.g., secondary to CABG, an interventional procedure,&#xD;
             pneumonia, or hyperthyroidism)&#xD;
&#xD;
          3. Patients who require long-term anticoagulation for a condition other than atrial&#xD;
             fibrillation&#xD;
&#xD;
          4. Patients not suitable for short term warfarin (including due to bleeding diathesis or&#xD;
             coagulopathy or absolute contraindication warfarin) or who will refuse transfusion&#xD;
&#xD;
          5. Patients with rheumatic mitral valve disease, known severe aortic stenosis requiring&#xD;
             surgical or percutaneous valve replacement, or existing mechanical valve prosthesis&#xD;
&#xD;
          6. Active infection with bacteremia&#xD;
&#xD;
          7. Known hypersensitivity or contraindication to aspirin, clopidogrel,&#xD;
             heparin/bivalirudin, any device material or component (nitinol, nickel, titanium,&#xD;
             PET), and/or contrast sensitivity that cannot be adequately pre-medicated&#xD;
&#xD;
          8. Anatomic conditions that would prevent performance of the LAA occlusion procedure&#xD;
             (e.g., prior atrial septal defect [ASD] or patient foramen ovale [PFO] surgical repair&#xD;
             or implanted closure device, or obliterated left atrial appendage)&#xD;
&#xD;
          9. Recent (within 30 days pre-procedure) or planned (within 60 days post procedure)&#xD;
             cardiac or non-cardiac interventional or surgical procedure (e.g., cardioversion,&#xD;
             ablation, percutaneous coronary intervention, cataract surgery, etc.)&#xD;
&#xD;
         10. Recent (within 90 days pre-procedure) stroke, transient ischemic attack, or myocardial&#xD;
             infarction&#xD;
&#xD;
         11. Severe heart failure (New York Heart Association Class IV)&#xD;
&#xD;
         12. Known asymptomatic carotid artery disease with&gt;70% diameter stenosis OR symptomatic&#xD;
             carotid disease (&gt;50% diameter stenosis with ipsilateral stroke or TIA). Subjects with&#xD;
             prior carotid endarterectomy or carotid stent placement may be enrolled, provided that&#xD;
             known diameter stenosis is &lt;50%.&#xD;
&#xD;
         13. Past or pending heart or any other organ transplant, or on the waiting list for any&#xD;
             organ transplant&#xD;
&#xD;
         14. Known other medical illness or known history of substance abuse that may cause&#xD;
             non-compliance with the protocol, confound data interpretation, or is associated with&#xD;
             a life expectancy of less than 2 years&#xD;
&#xD;
         15. Current participation in another investigational drug or device study&#xD;
&#xD;
        Echocardiographic Exclusion Criteria&#xD;
&#xD;
          1. Left atrial appendage anatomy may accommodate implantation of the WATCHMAN device.&#xD;
&#xD;
          2. LVEF &lt;30%&#xD;
&#xD;
          3. Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE within&#xD;
             2 days prior to implant&#xD;
&#xD;
          4. Presence of a high-risk patent foramen ovale (PFO), defined as an atrial septal&#xD;
             aneurysm (excursion &gt;15 mm or length &gt;15 mm) or large shunt (early, within 3 beats&#xD;
             and/or substantial passage of bubbles)&#xD;
&#xD;
          5. Moderate or severe mitral valve stenosis (mitral valve area &lt;1.5 cm2)&#xD;
&#xD;
          6. Complex atheroma with mobile plaque of the descending aorta and/or aortic arch (Grade&#xD;
             4 or higher)&#xD;
&#xD;
          7. Presence of a cardiac tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian O'Neill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian O'Neill, MD</last_name>
    <phone>313-916-8708</phone>
    <email>boneil3@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ardit Kacorri, MD</last_name>
    <phone>313-916-7452</phone>
    <email>akacorr1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ardit Kacorri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brian O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lansky AJ, Messé SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. Eur Heart J. 2018 May 14;39(19):1687-1697. doi: 10.1093/eurheartj/ehx037.</citation>
    <PMID>28171522</PMID>
  </reference>
  <reference>
    <citation>Mandalenakis Z, Von Koch L, Eriksson H, Dellborg M, Caidahl K, Welin L, Rosengren A, Hansson PO. The risk of atrial fibrillation in the general male population: a lifetime follow-up of 50-year-old men. Europace. 2015 Jul;17(7):1018-22. doi: 10.1093/europace/euv036. Epub 2015 Apr 4.</citation>
    <PMID>25842274</PMID>
  </reference>
  <reference>
    <citation>Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(8):949-53. Epub 2006 Mar 9.</citation>
    <PMID>16527828</PMID>
  </reference>
  <reference>
    <citation>Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.</citation>
    <PMID>11343485</PMID>
  </reference>
  <reference>
    <citation>Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation. 2013 Dec 3;128(23):2470-7. doi: 10.1161/CIRCULATIONAHA.113.002449. Epub 2013 Oct 8.</citation>
    <PMID>24103419</PMID>
  </reference>
  <reference>
    <citation>Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable Risk Factors and Atrial Fibrillation. Circulation. 2017 Aug 8;136(6):583-596. doi: 10.1161/CIRCULATIONAHA.116.023163. Review.</citation>
    <PMID>28784826</PMID>
  </reference>
  <reference>
    <citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8.</citation>
    <PMID>1866765</PMID>
  </reference>
  <reference>
    <citation>Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002 Oct 1;113(5):359-64.</citation>
    <PMID>12401529</PMID>
  </reference>
  <reference>
    <citation>Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999 Nov;82(5):547-54. Review.</citation>
    <PMID>10525506</PMID>
  </reference>
  <reference>
    <citation>Kong B, Liu Y, Huang H, Jiang H, Huang C. Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives. J Thorac Dis. 2015 Feb;7(2):199-203. doi: 10.3978/j.issn.2072-1439.2015.01.20. Review.</citation>
    <PMID>25713737</PMID>
  </reference>
  <reference>
    <citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.</citation>
    <PMID>17577005</PMID>
  </reference>
  <reference>
    <citation>January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. Review. Erratum in: J Am Coll Cardiol. 2014 Dec 2;64(21):2305-7.</citation>
    <PMID>24685669</PMID>
  </reference>
  <reference>
    <citation>Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004 Oct 19;110(16):2287-92. Epub 2004 Oct 11.</citation>
    <PMID>15477396</PMID>
  </reference>
  <reference>
    <citation>Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.</citation>
    <PMID>19762550</PMID>
  </reference>
  <reference>
    <citation>Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134. Epub 2010 Mar 18.</citation>
    <PMID>20299623</PMID>
  </reference>
  <reference>
    <citation>Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997 Dec;28(12):2382-9.</citation>
    <PMID>9412618</PMID>
  </reference>
  <reference>
    <citation>Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011 Oct 15;108(8):1136-40. doi: 10.1016/j.amjcard.2011.06.017. Epub 2011 Jul 26.</citation>
    <PMID>21798501</PMID>
  </reference>
  <reference>
    <citation>Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21;131(12):927-34.</citation>
    <PMID>10610643</PMID>
  </reference>
  <reference>
    <citation>Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006 Apr;37(4):1070-4. Epub 2006 Mar 9.</citation>
    <PMID>16528001</PMID>
  </reference>
  <reference>
    <citation>Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007 Aug 11;370(9586):493-503.</citation>
    <PMID>17693178</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Brian O'Neill</investigator_full_name>
    <investigator_title>Director of Interventional Cardiology Research</investigator_title>
  </responsible_party>
  <keyword>LAMBRE device</keyword>
  <keyword>Left Atrial Appendage Occlusion device</keyword>
  <keyword>CVA prevention</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Cardiovascular angiography</keyword>
  <keyword>Anti-coagulation management</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>nonvalvular atrial fibrillation</keyword>
  <keyword>non-pharmacological alternative</keyword>
  <keyword>Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

